Treatment of psoriasis with interferon induced Helicase C domain 1 (IFIH1) inhibitors

A method of treating a subject with a therapeutic agent that treats or inhibits psoriasis, wherein the subject has psoriasis, the method comprising the steps of:

• determining whether the subject has a Tripartite Motif Containing 65 (TRIM65) missense variant nucleic acid molecule encoding a TRIM65 predicted loss-of-function polypeptide by:
• obtaining or having obtained a biological sample from the subject;
• and
• performing or having performed a sequence analysis on the biological sample to determine if the subject has a genotype comprising the TRIM65 missense variant nucleic acid molecule;
• and
• administering or continuing to administer the therapeutic agent that treats or inhibits psoriasis in a standard dosage amount and/or administering a TRIM65 inhibitor to the subject that is TRIM65 reference;
• administering or continuing to administer the therapeutic agent that treats or inhibits psoriasis in an amount that is the same as or less than a standard dosage amount and/or administering a TRIM65 inhibitor to the subject that is heterozygous for the TRIM65 missense variant nucleic acid molecule;
• or
• administering or continuing to administer the therapeutic agent that treats or inhibits psoriasis in an amount that is the same as or less than a standard dosage amount to a subject that is homozygous for the TRIM65 missense variant nucleic acid molecule;
• wherein the presence of a genotype having the TRIM65 missense variant nucleic acid molecule encoding the TRIM65 polypeptide indicates the subject has a decreased risk of developing psoriasis;
• and
• wherein the TRIM65 inhibitor comprises an inhibitory nucleic acid molecule comprising an antisense nucleic acid molecule, a small interfering RNA (siRNA), or a short hairpin RNA (shRNA) that hybridizes to a TRIM65 nucleic acid molecule.